Smith & Nephew plc (LON:SN) Receives Consensus Rating of “Hold” from Analysts

Shares of Smith & Nephew plc (LON:SN) have earned a consensus recommendation of “Hold” from the six analysts that are covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is GBX 1,381.33.

Several brokerages recently issued reports on SN. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Smith & Nephew in a report on Friday, November 7th. Citigroup lifted their target price on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a research note on Friday, October 31st. Panmure Gordon reissued a “hold” rating and issued a GBX 1,200 target price on shares of Smith & Nephew in a report on Tuesday, December 9th. Royal Bank Of Canada cut Smith & Nephew to a “sector perform” rating and dropped their price target for the company from GBX 1,700 to GBX 1,350 in a report on Wednesday, December 17th. Finally, Berenberg Bank reiterated a “hold” rating and issued a GBX 1,300 price objective on shares of Smith & Nephew in a research report on Friday, January 23rd.

Smith & Nephew Stock Performance

Shares of LON SN opened at GBX 1,267 on Tuesday. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The firm’s 50-day moving average is GBX 1,234.95 and its two-hundred day moving average is GBX 1,293.76. The company has a market capitalization of £13.89 billion, a PE ratio of 45.62, a PEG ratio of 0.46 and a beta of 0.62.

Insider Transactions at Smith & Nephew

In other Smith & Nephew news, insider Deepak Nath sold 1,240 shares of the stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of GBX 1,257, for a total transaction of £15,586.80. 0.19% of the stock is currently owned by company insiders.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.